Ivonescimab inhibits both PD-1/PD-L1-mediated immune evasion and VEGF-driven angiogenesis, providing a dual mechanism of action that improves therapeutic effectiveness in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.